---
title: "Patient-derived cartilage-on-a-chip model for knee osteoarthritis captures donor and stressor-spec"
id: "biorxiv-11-human-knee-osteoarthritis-patient-specific-cartilage-on-a-chip-model-captures"
canonical_url: "https://medichelpline.com/clinical-feed/biorxiv-11-human-knee-osteoarthritis-patient-specific-cartilage-on-a-chip-model-captures"
content_type: "clinical_feed_article"
specialty: "Rheumatology"
source_name: "bioRxiv (Biomedical Preprints)"
source_url: "https://www.biorxiv.org/content/10.64898/2026.09.03.748852v1?rss=1"
published_at: "2026-09-07T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Patient-derived cartilage-on-a-chip model for knee osteoarthritis captures donor and stressor-spec
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/biorxiv-11-human-knee-osteoarthritis-patient-specific-cartilage-on-a-chip-model-captures
- **Specialty:** [Rheumatology](https://medichelpline.com/clinical-feed/rheumatology.md)
- **Primary Source:** bioRxiv (Biomedical Preprints)
- **Source URL:** [Original Journal Publication](https://www.biorxiv.org/content/10.64898/2026.09.03.748852v1?rss=1)
- **Published At:** 2026-09-07T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The authors developed a scalable, patient-derived **cartilage-on-a-chip** model (PD-CartChip) using end-stage knee osteoarthritis (KOA) cartilage explants integrated onto a microengineered platform. - The platform applies controlled **mechanical overloading** and **hyperinflammatory stressors** to reproduce different KOA etiologies and drive disease-relevant changes in tissue. - Stressors induced distinct, multivariable readouts across a curated panel of **anabolic and catabolic genes**, extracellular matrix (ECM) proteins, and soluble factors, demonstrating measurable molecular and biochemical responses in the model. - Exploratory analyses identified both **stressor-agnostic** and **stressor-specific KOA disease signatures** across coordinated model features, suggesting reproducible patterns despite heterogeneity. - Although the tissues were derived from end-stage KOA patients, the model showed improvements in response to **dexamethasone**, a symptom-modifying anti-inflammatory treatment used in KOA. - Responses to dexamethasone varied according to both applied stressor type and **donor heterogeneity**, indicating the platform captures patient-specific treatment variation. - Grouping coordinated model readouts provided proof-of-concept for predicting categories of patient responsiveness to candidate therapeutics. - Supplementing model results with annotated patient data supplied additional donor-dependent context to interpret responsiveness patterns. - The authors propose PD-CartChip as a research tool to help overcome donor and stressor heterogeneity barriers in development of disease-modifying osteoarthritis drugs (**DMOADs**). - Declarations note potential competing interests and funding sources; no additional experimental details, quantitative data, or specific predictive algorithms were reported in the abstract.
## Clinical Analysis & Structured Key Points
Human knee osteoarthritis patient-specific cartilage-on-a-chip model captures donor differences to stressors and treatments | bioRxiv Skip to main content New Results Human knee osteoarthritis patient-specific cartilage-on-a-chip model captures donor differences to stressors and treatments View ORCID Profile Lauren Banh , Kevin Perera , Brendan R. Lobo , Kara Walz , Ka Kit Cheung , Rik Chatterjee , Esme Bonnell , Kebin Li , Byeong-Ui Moon , Rajiv Gandhi , View ORCID Profile Edmond W. K. Young , View ORCID Profile Sowmya Viswanathan doi: https://doi.org/10.64898/2026.09.03.748852 Lauren Banh 1 University of Toronto; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Lauren Banh Kevin Perera 1 University of Toronto; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Brendan R. Lobo 1 University of Toronto; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Kara Walz 1 University of Toronto; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Ka Kit Cheung 1 University of Toronto; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Rik Chatterjee 1 University of Toronto; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Esme Bonnell 1 University of Toronto; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Kebin Li 2 National Research Council Canada; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Byeong-Ui Moon 2 National Research Council Canada; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Rajiv Gandhi 3 University Health Network Find this author on Google Scholar Find this author on PubMed Search for this author on this site Edmond W. K. Young 1 University of Toronto; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Edmond W. K. Young Sowmya Viswanathan 3 University Health Network Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Sowmya Viswanathan For correspondence: sowmya.viswanathan{at}uhn.ca Abstract Info/History Metrics Supplementary material Preview PDF Abstract Knee Osteoarthritis (KOA) is a progressive whole-joint disease without approved disease modifying OA drugs (DMOADs). Effective treatments have been hindered by multiple layers of heterogeneity, including diverse disease etiology and patient-to-patient variability. Here, we present a scalable, KOA patient-derived (PD) cartilage-on-a-chip (CartChip) model integrating end-stage KOA cartilage tissue explants on a microengineered platform that, under mechanical overloading and hyperinflammatory stressors, mimics different KOA etiologies. These stressors drove distinct multivariable model features, including changes in a curated panel of anabolic and catabolic genes, extracellular matrix protein and soluble factors. Exploratory analysis of coordinated model readouts identified stressor-agnostic and -specific KOA disease signatures. Despite using KOA tissue, the model showed improvements to dexamethasone, a symptom-modifying, anti-inflammatory KOA treatment. The model responses to dexamethasone were dependent on both stressor and donor heterogeneity. Exploratory groupings of coordinated model readouts provided proof-of-concept for predicting categories of patient responsiveness to test therapeutics. Annotating patient data provided additional donor-dependent contexts for interpreting model responsiveness. PD-CartChip provides a powerful research platform to potentially surmount the donor and stressor heterogeneity barrier in developing DMOADs. Competing Interest Statement S.V. has 60% ownership of Regulatory Cell Therapy Consultants Inc, which provides regulatory consulting advise for cell and gene therapy developers. E.Y. has 33% ownership of Velum Biosystems, Inc, which is developing advanced organ-on-a-chip technology with matrix membranes for tissue barrier modelling. These interests do not compete with the work presented here. Funder Information Declared Schroeder Arthritis Institute via the Toronto General and Western Hospital Foundation (University Health Network) Center for Research and Application of Fluidic Technologies (CRAFT) Project Award Arthritis Society, https://ror.org/00bpw5437 , 22-0000000123 Natural Sciences and Engineering Research Council of Canada (NSERC) Discovery Grants , RGPIN-2024-04118 , RGPIN 2018-05737 , RGPIN-2025-06905 , RGPIN 2019-05885 Copyright The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Back to top Previous Next Posted September 07, 2026. Download PDF Supplementary Material Email Thank you for your interest in spreading the word about bioRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Human knee osteoarthritis patient-specific cartilage-on-a-chip model captures donor differences to stressors and treatments Message Subject (Your Name) has forwarded a page to you from bioRxiv Message Body (Your Name) thought you would like to see this page from the bioRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Human knee osteoarthritis patient-specific cartilage-on-a-chip model captures donor differences to stressors and treatments Lauren Banh , Kevin Perera , Brendan R. Lobo , Kara Walz , Ka Kit Cheung , Rik Chatterjee , Esme Bonnell , Kebin Li , Byeong-Ui Moon , Rajiv Gandhi , Edmond W. K. Young , Sowmya Viswanathan bioRxiv 2026.09.03.748852; doi: https://doi.org/10.64898/2026.09.03.748852 Share This Article: Copy Citation Tools Human knee osteoarthritis patient-specific cartilage-on-a-chip model captures donor differences to stressors and treatments Lauren Banh , Kevin Perera , Brendan R. Lobo , Kara Walz , Ka Kit Cheung , Rik Chatterjee , Esme Bonnell , Kebin Li , Byeong-Ui Moon , Rajiv Gandhi , Edmond W. K. Young , Sowmya Viswanathan bioRxiv 2026.09.03.748852; doi: https://doi.org/10.64898/2026.09.03.748852 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Animal Behavior and Cognition (7969) Biochemistry (18623) Bioengineering (14765) Bioinformatics (44155) Biophysics (22458) Cancer Biology (19585) Cell Biology (26737) Clinical Trials (138) Developmental Biology (13900) Ecology (20880) Epidemiology (2067) Evolutionary Biology (25315) Genetics (16100) Genomics (23400) Immunology (18608) Microbiology (42209) Molecular Biology (17939) Neuroscience (92895) Paleontology (693) Pathology (2969) Pharmacology and Toxicology (5063) Physiology (8064) Plant Biology (15901) Scientific Communication and Education (2091) Synthetic Biology (4538) Systems Biology (10184) Zoology (2376)
## Related Clinical Research

- [Joint tissue explant model using psoriatic arthritis synovial fluid as a tool to capture patient-specific responses to treatments](https://medichelpline.com/clinical-feed/biorxiv-6-joint-tissue-explant-model-using-psoriatic-arthritis-synovial-fluid-as-a-tool.md)
- [OCTA quantifies choroidal and retinal thinning and blood flow loss in lens-induced myopia rats](https://medichelpline.com/clinical-feed/plos-one-17-quantitative-analysis-of-choroidal-and-retinal-thickness-and-blood-flow-in-a.md)
- [Poly(glutamic acid)-Based Microgels for Osteoarthritis: Durable Lubrication and MMP-Responsive Dex](https://medichelpline.com/clinical-feed/pubmed-42734288.md) (DOI: 10.1021/acs.biomac.6c00920)
- [Teclistamab vs lenalidomide–dexamethasone in high-risk smoldering multiple myeloma: randomized pha](https://medichelpline.com/clinical-feed/nature-1-teclistamab-versus-lenalidomide-dexamethasone-in-high-risk-smoldering-multiple.md)
- [Cathepsin K Generates Cis- and Trans-Spliced Peptides That May Form HLA-DR4–Restricted RA Autoanti](https://medichelpline.com/clinical-feed/biorxiv-4-cathepsin-k-mediates-the-formation-of-potential-rheumatoid-arthritis-relevant.md)

## Navigation
- [← Back to Rheumatology Feed](https://medichelpline.com/clinical-feed/rheumatology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.